Functional neovascularization of biodegradable dextran hydrogels with multiple angiogenic growth factors

Sun, Guozhe; Shen, Yun-Dun; Kusuma, Sravanti; Fox-Talbot, Karen; Steenbergen, Charles; Gerecht, Sharon

doi:10.1016/j.biomaterials.2010.08.091

Cited by 141 publications

(88 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As stated in the introduction, several studies have explored the potential benefits of GF combination, either by covalent grafting, [20,24] progressive release from a polymer scaffolds or nanoparticles, [15,16,19,21] capture by matrix [23] or oriented tethering. [17] To our knowledge, most studies were however focused on testing combinations of different GF at fixed concentrations, rather than varying their relative amounts and studying the biological effect brought by specific ratios.…”

Section: Discussionmentioning

confidence: 99%

“…[12][13][14][15] This generated a growing interest in biomimetic materials delivering or displaying multiple GFs. [15][16][17][18] Studies have shown that GF combination in biomaterials can improve angiogenesis, [17,[19][20][21][22] osteogenesis, [23] directed migration [24] or cell differentiation [23] when compared to a single GF. However, major hurdles still limit the use of systems involving multiple GF, such as the huge quantities of GF required for large size implants/scaffolds, or the lack of characterization of potential synergies existing between GF that could be exploited for enhanced implant biological activity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Controlled co-immobilization of EGF and VEGF to optimize vascular cell survival

et al. 2016

View full text Add to dashboard Cite

Growth factors (GFs) are potent signaling molecules that act in a coordinated manner in physiological processes such as tissue healing or angiogenesis. Co-immobilizing GFs on materials while preserving their bioactivity still represents a major challenge in the field of tissue regeneration and bioactive implants. In this study, we explore the potential of an oriented immobilization technique based on two high affinity peptides, namely the Ecoil and Kcoil, to allow for the simultaneous capture of the epidermal growth factor (EGF) and the vascular endothelial growth factor (VEGF) on a chondroitin sulfate coating. This glycosaminoglycan layer was selected as it promotes cell adhesion but reduces non-specific adsorption of plasma proteins. We demonstrate here that both Ecoiltagged GFs can be successfully immobilized on chondroitin sulfate surfaces that had been pre-decorated with the Kcoil peptide. As shown by direct ELISA, changing the incubation concentration of the various GFs enabled to control their grafted amount.Moreover, cell survival studies with endothelial and smooth muscle cells confirmed that our oriented tethering strategy preserved GF bioactivity. Of salient interest, coimmobilizing EGF and VEGF led to better cell survival compared to each GF captured alone, suggesting a synergistic effect of these GFs. Altogether, these results demonstrate the potential of coiled-coil oriented GF tethering for the co-immobilization of macromolecules; it thus open the way to the generation of biomaterials surfaces with fine-tuned biological properties.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Controlled co-immobilization of EGF and VEGF to optimize vascular cell survival

et al. 2016

View full text Add to dashboard Cite

show abstract

“…180 It has also been reported that the coadministration of VEGF, IGF-1, stromal-derived growth factor (SDF)-1, and Ang-1 led to a dramatic increase in angiogenic response, specifically the size and number of arterioles when compared to the single delivery of these individual factors. 154 Another interesting group of studies involve the use of chemoattractant chemokines selected to promote host cell migration. For example, SDF-1 chemotactic gradients have been shown to affect migration patterns of both injected and host MSCs.…”

Section: From Single To Multiple Bioactive Factor Delivery For Skeletmentioning

confidence: 99%

Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery

Santo

Gomes²,

Mano³

et al. 2013

Tissue Engineering Part B: Reviews

105

View full text Add to dashboard Cite

The development of controlled release systems for the regeneration of bone, cartilage, and osteochondral interface is one of the hot topics in the field of tissue engineering and regenerative medicine. However, the majority of the developed systems consider only the release of a single growth factor, which is a limiting step for the success of the therapy. More recent studies have been focused on the design and tailoring of appropriate combinations of bioactive factors to match the desired goals regarding tissue regeneration. In fact, considering the complexity of extracellular matrix and the diversity of growth factors and cytokines involved in each biological response, it is expected that an appropriate combination of bioactive factors could lead to more successful outcomes in tissue regeneration. In this review, the evolution on the development of dual and multiple bioactive factor release systems for bone, cartilage, and osteochondral interface is overviewed, specifically the relevance of parameters such as dosage and spatiotemporal distribution of bioactive factors. A comprehensive collection of studies focused on the delivery of bioactive factors is also presented while highlighting the increasing impact of platelet-rich plasma as an autologous source of multiple growth factors.

show abstract

“…Significant work in this area has been undertaken using the sister compound IGF1 (Jaklenec et al 2008, Chen et al 2009, Sun et al 2011, Kim et al 2012. In one example, Nelson et al (2011) used porous poly(ester urethane)urea scaffolds to demonstrate the long-term delivery of bioactive IGF1 in vitro.…”

Section: Apoptosis In Islet Transplantation: the Role For Pro-inflammmentioning

confidence: 99%

IGF2: an endocrine hormone to improve islet transplant survival

Hughes¹,

Rojas-Canales²,

Drogemuller³

et al. 2014

Journal of Endocrinology

View full text Add to dashboard Cite

In the week following pancreatic islet transplantation, up to 50% of transplanted islets are lost due to apoptotic cell death triggered by hypoxic and pro-inflammatory cytokinemediated cell stress. Thus, therapeutic approaches designed to protect islet cells from apoptosis could significantly improve islet transplant success. IGF2 is an anti-apoptotic endocrine protein that inhibits apoptotic cell death through the mitochondrial (intrinsic pathway) or via antagonising activation of pro-inflammatory cytokine signalling (extrinsic pathway), in doing so IGF2 has emerged as a promising therapeutic molecule to improve islet survival in the immediate post-transplant period. The development of novel biomaterials coated with IGF2 is a promising strategy to achieve this. This review examines the mechanisms mediating islet cell apoptosis in the peri-and post-transplant period and aims to identify the utility of IGF2 to promote islet survival and enhance long-term insulin independence rates within the setting of clinical islet transplantation.

show abstract

Functional neovascularization of biodegradable dextran hydrogels with multiple angiogenic growth factors

Cited by 141 publications

References 41 publications

Controlled co-immobilization of EGF and VEGF to optimize vascular cell survival

Controlled co-immobilization of EGF and VEGF to optimize vascular cell survival

Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery

IGF2: an endocrine hormone to improve islet transplant survival

Contact Info

Product

Resources

About